Skip to main content

Table 1 Characteristics of women ≥29 years who sought cervical cancer screening services through NJCEED, overall and among those who ever had a high-risk human papilloma virus (HR-HPV) DNA test and those who ever received a positive HR-HPV test result, 2009–2015

From: Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women

Patient-level characteristics

Total, N = 50,510

Ever had a HR-HPV DNA test, n = 13,440*

 

Ever received a positive HR-HPVtest result, n = 1792**

 

n (%)

n (%)

P a

n (%)

P b

Sociodemographics

 Age at enrollment into NJCEED (years)

  

< 0.001

 

< 0.001

  29–39

7987 (15.8)

2457 (18.3)

 

532 (29.7)

 

  40–49

19,909 (39.4)

5663 (42.1)

 

689 (38.4)

 

   ≥ 50

22,614 (44.8)

5320 (39.6)

 

571 (31.9)

 

 Race/ethnicity

  

< 0.001

 

< 0.001

  Non-Hispanic White

12,420 (24.6)

2706 (20.1)

 

443 (24.7)

 

  Non-Hispanic Black

7716 (15.3)

1993 (14.8)

 

247 (13.8)

 

  Asian/Pacific Islander

3351 (6.6)

1060 (7.9)

 

98 (5.5)

 

  Hispanic

27,023 (53.5)

7681 (57.2)

 

1004 (56.0)

 

 Place of birth

  

< 0.001

 

< 0.001

  USA

14,695 (29.1)

3468 (25.8)

 

525 (29.3)

 

  Central and South America

20,437 (40.5)

5575 (41.5)

 

754 (42.1)

 

  Caribbean

7266 (14.4)

2007 (14.9)

 

261 (14.6)

 

  Africa

952 (1.9)

243 (1.8)

 

19 (1.1)

 

  Asia and the Middle East

3283 (6.5)

1075 (8.0)

 

95 (5.3)

 

  Europe, Russia and Australia and Oceania

1549 (3.1)

546 (4.1)

 

61 (3.4)

 

  Other countriesc

2328 (4.6)

526 (3.9)

 

77 (4.3)

 

Cervical cancer screening characteristics

 Number of cervical screening visits

  

< 0.001

 

< 0.001

  1

29,872 (59.1)

7399 (55.1)

 

842 (47.0)

 

  2

8760 (17.3)

2488 (18.5)

 

356 (19.9)

 

   ≥ 3

11,878 (23.5)

3553 (26.4)

 

594 (33.1)

 

 Number of Pap tests

  

< 0.001

  

  0

1571 (3.1)

10 (0.1)

 

4 (0.2)

 

  1

35,670 (70.6)

8488 (63.2)

 

967 (54.0)

 

  2

8347 (16.5)

2717 (20.2)

 

379 (21.1)

 

   ≥ 3

4922 (9.7)

2230 (16.6)

 

442 (24.7)

 

 Age at first Pap test (years)

  

< 0.001

  

  29–39

7778 (15.9)

2450 (18.2)

 

529 (29.6)

 

  40–49

19,291 (39.4)

5658 (42.1)

 

688 (38.5)

 

   ≥ 50

21,870 (44.7)

5322 (39.6)

 

571 (31.9)

 

 Number of HPV tests

  

< 0.001

 

< 0.001

  0

37,070 (73.4)

0 (0.0)

 

0 (0.0)

 

  1

11,810 (23.4)

11,810 (87.9)

 

1391 (77.6)

 

  2

1386 (2.7)

1386 (10.3)

 

306 (17.1)

 

   ≥ 3

244 (0.5)

244 (1.8)

 

95 (5.3)

 

 Age at first HPV test (years)

  

–

 

< 0.001

  29–39

 

2307 (17.2)

 

514 (28.7)

 

  40–49

 

5461 (40.6)

 

673 (37.6)

 

   ≥ 50

 

5672 (42.2)

 

605 (33.8)

 
  1. Abbreviations: FPL federal poverty level, HR-HPV high-risk human papillomavirus, NJCEED New Jersey Cancer Early Education and Detection, USA United States of America, ZCTA ZIP Code Tabulation Area. Bolded values represent statistically significant associations (P <0.05)
  2. *Of the 50,510 NJCEED patients ≥29 years included in the analytic sample, 13,440 (26.6%) had at least one HR-HPV DNA test
  3. **Of the 13,440 NJCEED patients ≥29 years included in the analytic sample, 1792 (13.3%) had at least one positive HR-HPV DNA test result
  4. aP-values were calculated using chi-square tests comparing women who ever had a HR-HPV DNA test to those who did not
  5. bP-values were calculated using chi-square tests comparing women who ever had a positive HR-HPV DNA test result to those who did not
  6. cIncludes women born in Canada as well as those reporting other or unspecified countries outside the USA